Zhejiang University

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

200

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

32 drugs in development

Phase 33

Phase 24

Phase 122

Preclinical2

By Therapeutic Area

top 3

Oncology

2784%

Immunology

26%

Cardiovascular

13%

R&D Momentum

77/100

Pipeline Velocity

42/100

Trial Completion Rate

73/100

Pipeline Concentration

72/100

Pipeline Freshness

59/100

Strategic Signals

↗Active in Immunology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 8, 2026

Active, not recruiting

Clinical Research on the Use of Abdominal CT Combined With AI for Early Screening

Jul 2, 2026

Completed

The Effect of Focused Attention and Open Monitoring Meditation on Creativity in Scientific Researchers

Earlier

Mar 30, 2026TrialSafety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma

Feb 28, 2026TrialClinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Feb 15, 2026TrialHRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Feb 1, 2026TrialIBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer

Jan 16, 2026TrialTEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients

Dec 31, 2025TrialA Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer

4 more events

Dec 15, 2025TrialT Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Dec 5, 2025TrialEvaluation of Diaphragmatic Function After Interscalene Block With Liposomal Bupivacaine

Nov 30, 2025TrialIL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia

Nov 30, 2025TrialA Multicenter Study of CAR-T Cells in Primary Ph+All

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(1 drug)

—

Cardiovascular(1 drug)

Immunology(2 drugs)

—

Immunology(2 drugs)

Oncology(27 drugs)

—

Oncology(27 drugs)

Unknown / Other(2 drugs)

—

Unknown / Other(2 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)